Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Timothy P Hughes

Showing results (71-80 of 205) with videos related to

Pageof 21
Sort By:
Haematologica|October 16, 2012
Dasatinib targets chronic myeloid leukemia-CD34+ progenitors as effectively as it targets mature cellsDevendra K Hiwase, Verity A Saunders, Eva Nievergall, et al.
British Journal of Cancer|December 4, 2019
The effect of co-occurring lesions on leukaemogenesis and drug response in T-ALL and ETP-ALLPaniz Tavakoli Shirazi, Laura N Eadie, Susan L Heatley, et al.
Blood|January 5, 2017
CML patients with deep molecular responses to TKI have restored immune effectors and decreased PD-1 and immune suppressorsAmy Hughes, Jade Clarson, Carine Tang, et al.
Nature|July 1, 2005
Dynamics of chronic myeloid leukaemiaFranziska Michor, Timothy P Hughes, Yoh Iwasa, et al.
Blood|July 5, 2014
Many BCR-ABL1 compound mutations reported in chronic myeloid leukemia patients may actually be artifacts due to PCR-mediated recombinationWendy T Parker, Stuart R Phillis, David T O Yeung, et al.
Blood|October 27, 2015
KIR2DL5B genotype predicts outcomes in CML patients treated with response-directed sequential imatinib/nilotinib strategyDavid T Yeung, Carine Tang, Ljiljana Vidovic, et al.
Leukemia|June 11, 2026
Direct measurement of in vivo BCR::ABL1 kinase inhibition reveals stronger potency of asciminib as compared with imatinib and nilotinibChung Hoow Kok, Naranie Shanmuganathan, Verity A Saunders, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 13, 2011
Sensitive detection of BCR-ABL1 mutations in patients with chronic myeloid leukemia after imatinib resistance is predictive of outcome during subsequent therapyWendy T Parker, Rebecca M Lawrence, Musei Ho, et al.
Blood Cancer Journal|September 11, 2023
Adverse outcomes for chronic myeloid leukemia patients with splenomegaly and low in vivo kinase inhibition on imatinibChung H Kok, Verity A Saunders, Phuong Dang, et al.
Scientific Reports|August 11, 2023
The acquisition order of leukemic drug resistance mutations is directed by the selective fitness associated with each resistance mechanismBenjamin C S Leow, Chung H Kok, David T Yeung, et al.
Pageof 21

Showing results (71-80 of 205) with videos related to

Sort By:
Pageof 21
Haematologica|October 16, 2012
Dasatinib targets chronic myeloid leukemia-CD34+ progenitors as effectively as it targets mature cellsDevendra K Hiwase, Verity A Saunders, Eva Nievergall, et al.
British Journal of Cancer|December 4, 2019
The effect of co-occurring lesions on leukaemogenesis and drug response in T-ALL and ETP-ALLPaniz Tavakoli Shirazi, Laura N Eadie, Susan L Heatley, et al.
Blood|January 5, 2017
CML patients with deep molecular responses to TKI have restored immune effectors and decreased PD-1 and immune suppressorsAmy Hughes, Jade Clarson, Carine Tang, et al.
Nature|July 1, 2005
Dynamics of chronic myeloid leukaemiaFranziska Michor, Timothy P Hughes, Yoh Iwasa, et al.
Blood|July 5, 2014
Many BCR-ABL1 compound mutations reported in chronic myeloid leukemia patients may actually be artifacts due to PCR-mediated recombinationWendy T Parker, Stuart R Phillis, David T O Yeung, et al.
Blood|October 27, 2015
KIR2DL5B genotype predicts outcomes in CML patients treated with response-directed sequential imatinib/nilotinib strategyDavid T Yeung, Carine Tang, Ljiljana Vidovic, et al.
Leukemia|June 11, 2026
Direct measurement of in vivo BCR::ABL1 kinase inhibition reveals stronger potency of asciminib as compared with imatinib and nilotinibChung Hoow Kok, Naranie Shanmuganathan, Verity A Saunders, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 13, 2011
Sensitive detection of BCR-ABL1 mutations in patients with chronic myeloid leukemia after imatinib resistance is predictive of outcome during subsequent therapyWendy T Parker, Rebecca M Lawrence, Musei Ho, et al.
Blood Cancer Journal|September 11, 2023
Adverse outcomes for chronic myeloid leukemia patients with splenomegaly and low in vivo kinase inhibition on imatinibChung H Kok, Verity A Saunders, Phuong Dang, et al.
Scientific Reports|August 11, 2023
The acquisition order of leukemic drug resistance mutations is directed by the selective fitness associated with each resistance mechanismBenjamin C S Leow, Chung H Kok, David T Yeung, et al.
Pageof 21